HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The main purpose of this research study is to learn whether the investigational combination
of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive
breast cancer and BRCA1 or BRCA2 mutations.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania